Guilan Wen

机构：Nanchang University, Guizhou University, Guizhou Minzu University, Green Chemistry, First Affiliated Hospital of Nanchang University

发表论文 14 篇 · 总被引 559 次 · h-index 4

代表论文

• Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer (2022 · JAMA · 被引 480)
• Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study. (2022 · Journal of Clinical Oncology · 被引 35)
• First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial (2025 · 癌症：英文版 · 被引 21)
• Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study. (2024 · Journal of Clinical Oncology · 被引 6)
• Strategies for combating FIPV infection: antiviral agents and vaccines (2025 · Research in Veterinary Science · 被引 3)
• EDC3 protein of P-body suppresses PRRSV proliferation and functions by upregulating MyD88 (2025 · Veterinary Microbiology · 被引 2)